• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Savara, Inc. - Common Stock (NQ:SVRA)

    5.165 -0.065 (-1.24%)
    Streaming Delayed Price Updated: 12:22 PM EDT, Mar 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 734,748
    Open 5.250
    Bid (Size) 5.160 (3,000)
    Ask (Size) 5.170 (2,300)
    Prev. Close 5.230
    Today's Range 5.115 - 5.260
    52wk Range 1.890 - 7.005
    Shares Outstanding 114,066,080
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    VR Adviser Adds Over 1 Million Savara Shares ↗
    This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
    From Savara Inc.
    Via Business Wire

    Performance

    YTD
    -8.4%
    -8.4%
    1 Month
    -9.9%
    -9.9%
    3 Month
    -21.9%
    -21.9%
    6 Month
    +43.1%
    +43.1%
    1 Year
    +83.8%
    +83.8%

    More News

    Read More
    News headline image
    Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Announces Participation in 2026 Citizens Life Sciences Conference
    From Savara Inc.
    Via Business Wire
    News headline image
    SVRA Stock Rises After Hours As FDA Grants Priority Review For Lung Disorder Therapy ↗
    Via Stocktwits
    Topics Intellectual Property Lawsuit
    Get insights into the top gainers and losers of Friday's after-hours session. ↗
    Via Chartmill
    News headline image
    Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Announces New Employment Inducement Grant
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Announces Participation in Upcoming Investor Healthcare Conferences
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
    From Savara Inc.
    Via Business Wire
    News headline image
    SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Savara Announces New Employment Inducement Grant
    From Savara Inc.
    Via Business Wire
    News headline image
    PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
    From Savara Inc.
    Via Business Wire
    What's going on in today's pre-market session ↗
    Via Chartmill
    News headline image
    Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Announces Participation in Upcoming Investor Healthcare Conferences
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Savara Inc.
    Via Business Wire
    News headline image
    SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Class Action Filed Against Savara Inc. (SVRA) - November 7, 2025 Deadline to Join - Contact Levi & Korsinsky
    Via NewMediaWire
    Topics Fraud Lawsuit
    News headline image
    Class Action Filed Against Savara Inc. (SVRA) - November 7, 2025 Deadline to Join - Contact Levi & Korsinsky
    Via TheNewswire.com
    Topics Fraud Lawsuit
    News headline image
    Deadline Soon: Savara Inc. (SVRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    News headline image
    SAVARA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Savara Stockholders to Contact the Firm Before November 7th
    From Bragar Eagel & Squire
    Via GlobeNewswire

    Frequently Asked Questions

    Is Savara, Inc. - Common Stock publicly traded?
    Yes, Savara, Inc. - Common Stock is publicly traded.
    What exchange does Savara, Inc. - Common Stock trade on?
    Savara, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Savara, Inc. - Common Stock?
    The ticker symbol for Savara, Inc. - Common Stock is SVRA on the Nasdaq Stock Market
    What is the current price of Savara, Inc. - Common Stock?
    The current price of Savara, Inc. - Common Stock is 5.165
    When was Savara, Inc. - Common Stock last traded?
    The last trade of Savara, Inc. - Common Stock was at 03/17/26 12:22 PM ET
    What is the market capitalization of Savara, Inc. - Common Stock?
    The market capitalization of Savara, Inc. - Common Stock is 589.15M
    How many shares of Savara, Inc. - Common Stock are outstanding?
    Savara, Inc. - Common Stock has 589M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.